Search results for "emission [gravitational radiation]"

showing 10 items of 614 documents

Asymmetry in dopamine D2/3 receptors of caudate nucleus is lost with age

2007

Molecular and functional imaging techniques reveal evidence for lateralization of human cerebral function. Based on animal data, we hypothesized that asymmetry in dopamine neurotransmission declines during normal aging. In order to test this hypothesis, we measured dopamine D2/3 receptor availability with [18F]desmethoxyfallypride-PET (DMFP) in putamen and caudate nucleus (NC) of 21 healthy, right-handed males (24-60 years; 35+/-10). For volumetric analysis, high-resolution T1-weighted MR-images were obtained in 18 of the PET-subjects in order to assess possible age-related decreases in NC and putamen volume. The calculated DMFP binding potentials (BP) showed a right-ward asymmetry in NC of…

AdultMaleAgingmedicine.medical_specialtyCognitive NeuroscienceCaudate nucleusNeurotransmissionFunctional LateralityLateralization of brain functionAnimal dataDopamineDopamine receptor D2Internal medicineSalicylamidesmedicineHumansTissue DistributionReceptors Dopamine D2PutamenReceptors Dopamine D3Middle AgedEndocrinologyNeurologyDopamine receptorPositron-Emission TomographyCaudate NucleusRadiopharmaceuticalsPsychologyNeurosciencemedicine.drugNeuroImage
researchProduct

Central correlation of muscle sympathetic nerve activation during baroreflex unloading - a microneurography-positron emission tomography study

2013

The baroreceptor reflex controls spontaneous fluctuations in blood pressure. One major control variable of the baroreflex is the sympathetic vasoconstrictor activity to muscles [MSNA; burst frequency (BF) and burst incidence (BI)], which can be quantitatively assessed by microneurography. We aimed to investigate the central regions involved in baroreflex regulation of MSNA. Healthy men (mean age 25 years) participated in three experimental sessions. (i) Microneurography recordings of MSNA from the left peroneal nerve during rest and baroreflex unloading, induced by lower body negative pressure (LBNP; -40 mmHg). If MSNA could be reliably recorded throughout this procedure (n = 15), the subje…

AdultMaleBaroreceptorbusiness.industryGeneral NeuroscienceBrainPeroneal NerveRostral ventrolateral medullaMicroneurographyBaroreflexBaroreflexGlucoseBlood pressureOrgan SpecificityPositron-Emission TomographyAnesthesiaMedulla oblongataHumansMedicineBrainstemMuscle SkeletalbusinessMedullaEuropean Journal of Neuroscience
researchProduct

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

2017

GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab–bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2–6; and bendamustine 70/90 mg/m2 D1 and D2 of C1–6. The primary endpoint was safety/tolerability. Grade ≥3 adverse events (AEs) occurred in 82.3% of patients, including neutropenia (49.4%), thrombocytopenia (12.0%) and febrile neutropenia (10.8%). Serious AEs included neut…

AdultMaleBendamustineCancer Researchmedicine.medical_specialtyNeoplasm ResidualNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBendamustine HydrochlorideHumansSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryRemission InductionHematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellMinimal residual diseaseSurvival RateTumor lysis syndromeOncologyTolerabilitychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRituximabbusinessFebrile neutropeniaFollow-Up Studies030215 immunologymedicine.drugLeukemia
researchProduct

Differential contributions of ankle plantarflexors during submaximal isometric muscle action: A PET and EMG study

2014

Abstract The objective of this study was to investigate the relative contributions of superficial and deep ankle plantarflexors during repetitive submaximal isometric contractions using surface electromyography (SEMG) and positron emission tomography (PET). Myoelectric signals were obtained from twelve healthy volunteers (27.3±4.2yrs). A tracer ([ 18 F]-FDG) was injected during the exercise and PET scanning was done immediately afterwards. The examined muscles included soleus (Sol), medial gastrocnemius (MG), lateral gastrocnemius (LG), and flexor hallucis longus (FHL). It was found that isometric maximal voluntary contraction (MVC) force, muscle glucose uptake (GU) rate, and SEMG of variou…

AdultMaleBiophysicsNeuroscience (miscellaneous)Isometric exerciseElectromyographyYoung AdultMuscle actionIsometric ContractionHealthy volunteersmedicineHumansExercise physiologyMuscle Skeletalta315ExerciseLegArthrometry Articularmedicine.diagnostic_testElectromyographybusiness.industryBiomechanicsAnatomymusculoskeletal systemMagnetic Resonance ImagingHealthy VolunteersGlucosemedicine.anatomical_structureFlexor hallucis longusPositron-Emission TomographyFemaleNeurology (clinical)AnkleAnklebusinessNuclear medicineJournal of Electromyography and Kinesiology
researchProduct

[18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation

2003

The nucleoside 5-fluoro-2-deoxyuridine is a pyrimidine analogue accumulating in proliferative cells. We prospectively evaluated biodistribution of the PET tracer [(18)F]5-fluoro-2-deoxyuridine (FdUrd), its value for imaging malignant tumors, and its correlation to both [(18)F]2-fluoro-2-deoxyglucose (FDG)-PET findings and histological proliferation indices. In 11 previously untreated patients (5 lung carcinoma; 3 soft tissue sarcoma; 2 gastrointestinal carcinoma; 1 non-Hodgkin lymphoma [NHL]), mean doses of 290 MBq FdUrd and 390 MBq FDG were administered intravenously on subsequent days. Static PET scans were initiated 50-70 min after administration and the mean standardized uptake values (…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsProliferation indexUrinary BladderKidneyBone and BonesPyrimidine analogueFluorodeoxyglucose F18NeoplasmsmedicineCarcinomaHumansTissue DistributionRadiology Nuclear Medicine and imagingProspective StudiesAgedGastrointestinal NeoplasmsNeoplasm StagingPharmacologymedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinSoft tissue sarcomaKidney metabolismSarcomaGeneral MedicineMiddle Agedmedicine.diseaseLymphomaKi-67 AntigenLiverOncologyPositron emission tomographyFemaleSarcomaRadiopharmaceuticalsbusinessNuclear medicineCell DivisionTomography Emission-Computed
researchProduct

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

2014

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)…

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentMedizinDrug resistanceHematopoietic stem cell transplantationMastocytosis SystemicInternal medicinemedicineHumansTransplantation HomologousSystemic mastocytosisChildSurvival rateAgedRetrospective StudiesmastocytosisHematologybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationORIGINAL REPORTSMiddle Agedmedicine.diseaseMast cell leukemia3. Good healthSurvival RateTransplantationSettore MED/15 - MALATTIE DEL SANGUEHaematopoiesisTreatment OutcomeOncologyImmunologyCancer researchFemalebusinesstransplantation
researchProduct

Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck

1995

Despite considerable progress achieved in the management of head and neck carcinomas (HNC) in the last decade, the prognosis of patients with advanced squamous cell HNC is still dismal. On the basis of the reported good activity of a new vinca alkaloid derivative, i.e., vinorelbine (VNR), we tested the combination of cisplatin and VNR in a series of patients with recurrent or previously untreated unresectable squamous cell HNC. Thirty-five patients with recurrent or previously untreated unresectable squamous cell HNC were treated with a combination of cisplatin 80 mg/m2 on day 1, plus vinorelbine 25 mg/m2 i.v. push on days 1 and 8. This cycle was repeated every 3 weeks. Analysis of response…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentVinblastineVinorelbineGastroenterologyDrug Administration ScheduleVinca alkaloidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCisplatinChemotherapybusiness.industryRemission InductionVinorelbineMiddle AgedVinblastineSurgeryRadiation therapyRegimenOncologyHead and Neck NeoplasmsCarcinoma Squamous CellVomitingFemaleCisplatinNeoplasm Recurrence Localmedicine.symptombusinessmedicine.drug
researchProduct

High opiate receptor binding potential in the human lateral pain system

2005

To determine how opiate receptor distribution is co-localized with the distribution of nociceptive areas in the human brain, eleven male healthy volunteers underwent one PET scan with the subtype-nonselective opioidergic radioligand [(18)F]fluoroethyl-diprenorphine under resting conditions. The binding potential (BP), a parameter for the regional cerebral opioid receptor availability, was computed using the occipital cortex as reference region. The following regions of interest (ROIs) were defined on individual MR images: thalamus, sensory motor strip (SI/MI area), frontal operculum, parietal operculum, anterior insular cortex, posterior insular cortex, anterior cingulate cortex (ACC; peri-…

AdultMaleCingulate cortexCognitive NeuroscienceThalamusCaudate nucleusDiprenorphinePainInsular cortexbehavioral disciplines and activitiesCortex (anatomy)medicineHumansOperculum (brain)Anterior cingulate cortexbusiness.industryPutamenBrainNociceptorsAnatomyMiddle AgedMagnetic Resonance Imagingmedicine.anatomical_structurenervous systemNeurologyPositron-Emission TomographyReceptors Opioidbusinesspsychological phenomena and processesNeuroImage
researchProduct

Temsirolimus for the treatment of mantle cell lymphoma.

2010

Although recent progress has been made in the treatment of mantle cell lymphoma (MCL) the majority of patients experience relapse and ultimately die of their disease. The translocation t(11;14) is a prerequisite for the diagnosis of MCL and results in overexpression of cyclin D1. Its protein translation is controlled by mTOR, a key element of the PI3K/Akt pathway, and mTOR constitutes an attractive therapeutic target. Temsirolimus, a specific inhibitor of mTOR, has been evaluated in two Phase II trials in patients with relapsed MCL, and promising response rates up to 40% were found. Subsequently, a randomized Phase III trial was initiated, in which superiority in remission induction and pro…

AdultMaleCombination therapyChromosomal translocationAntineoplastic AgentsLymphoma Mantle-CellPharmacologyDisease-Free SurvivalDrug Administration ScheduleCyclin D1hemic and lymphatic diseasesmedicineSecondary PreventionHumansCyclin D1PI3K/AKT/mTOR pathwayAgedAged 80 and overSirolimusClinical Trials as Topicbusiness.industryTOR Serine-Threonine KinasesRemission InductionIntracellular Signaling Peptides and ProteinsHematologyMiddle Agedmedicine.diseaseTemsirolimusNon-Hodgkin's lymphomaRegimenCancer researchMantle cell lymphomaFemalebusinessmedicine.drugExpert review of hematology
researchProduct

Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas

2010

Quetiapine is next to clozapine an antipsychotic agent that exerts hardly any extrapyramidal side-effects at clinical efficacious doses. Some previous receptor occupancy studies reported preferential extrastriatal D2/3 receptor (D2/3R)-binding properties of second-generation antipsychotics and suggested this as possible reason for improved tolerability. This positron emission tomography (PET) investigation was designed to compare the occupancy of dopamine D2/3Rs by quetiapine in striatal and extrastriatal brain regions. Therefore, a cohort of 16 quetiapine-treated psychotic patients underwent an [18F]fallypride (FP) PET scan. Due to the high affinity of FP and its comparatively long half-li…

AdultMaleDibenzothiazepinesPyrrolidinesCaudate nucleusPharmacologyBinding CompetitiveQuetiapine FumarateYoung AdultQuetiapine FumarateDopamine receptor D2HumansMedicinePharmacology (medical)ClozapineVisual CortexPharmacologyTemporal cortexReceptors Dopamine D2business.industryReceptors Dopamine D3Binding potentialMiddle AgedCorpus StriatumTemporal LobePsychiatry and Mental healthFallypridePositron-Emission TomographyBenzamidesSchizophreniaQuetiapineFemalebusinessAntipsychotic Agentsmedicine.drugThe International Journal of Neuropsychopharmacology
researchProduct